Natalia Allué1, Pietro Chiarello2, Enrique Bernal Delgado3, Xavier Castells4, Priscila Giraldo5, Natalia Martínez6, Eugenia Sarsanedas7, Francesc Cots8. 1. Servicio de Control de Gestión, Hospital del Mar-Parc de Salut MAR, Barcelona, España; Servicio de Epidemiología y Evaluación, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, España; Unidad Docente de Medicina Preventiva y Salud Pública Hospital del Mar-Universitat Pompeu Fabra, Agència de Salut Pública de Barcelona, Barcelona, España; Programa de doctorado en Salud Pública, Departament de Pediatria, d'Obstetrícia i Ginecologia i de Medicina Preventiva, Universitat Autònoma de Barcelona, Barcelona, España. 2. Servicio de Control de Gestión, Hospital del Mar-Parc de Salut MAR, Barcelona, España; Servicio de Epidemiología y Evaluación, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, España; Programa de doctorado en Salud Pública, Departament de Pediatria, d'Obstetrícia i Ginecologia i de Medicina Preventiva, Universitat Autònoma de Barcelona, Barcelona, España. 3. Instituto de Investigación Sanitaria de Aragón (ISS Aragón), Zaragoza, España; Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), España. 4. Servicio de Epidemiología y Evaluación, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, España; Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), España. 5. Servicio de Epidemiología y Evaluación, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, España. 6. Instituto de Investigación Sanitaria de Aragón (ISS Aragón), Zaragoza, España. 7. Servicio de Documentación Clínica, Hospital del Mar-Parc de Salut MAR, Barcelona, España. 8. Servicio de Control de Gestión, Hospital del Mar-Parc de Salut MAR, Barcelona, España; Servicio de Epidemiología y Evaluación, IMIM (Institut Hospital del Mar d'Investigacions Mèdiques), Barcelona, España; Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), España. Electronic address: fcots@parcdesalutmar.cat.
Abstract
OBJECTIVE: To evaluate the incidence and costs of adverse events registered in an administrative dataset in Spanish hospitals from 2008 to 2010. METHODS: A retrospective study was carried out that estimated the incremental cost per episode, depending on the presence of adverse events. Costs were obtained from the database of the Spanish Network of Hospital Costs. This database contains data from 12 hospitals that have costs per patient records based on activities and clinical records. Adverse events were identified through the Patient Safety Indicators (validated in the Spanish Health System) created by the Agency for Healthcare Research and Quality together with indicators of the EuroDRG European project. RESULTS: This study included 245,320 episodes with a total cost of 1,308,791,871€. Approximately 17,000 patients (6.8%) experienced an adverse event, representing 16.2% of the total cost. Adverse events, adjusted by diagnosis-related groups, added a mean incremental cost of between €5,260 and €11,905. Six of the 10 adverse events with the highest incremental cost were related to surgical interventions. The total incremental cost of adverse events was € 88,268,906, amounting to an additional 6.7% of total health expenditure. CONCLUSIONS: Assessment of the impact of adverse events revealed that these episodes represent significant costs that could be reduced by improving the quality and safety of the Spanish Health System.
OBJECTIVE: To evaluate the incidence and costs of adverse events registered in an administrative dataset in Spanish hospitals from 2008 to 2010. METHODS: A retrospective study was carried out that estimated the incremental cost per episode, depending on the presence of adverse events. Costs were obtained from the database of the Spanish Network of Hospital Costs. This database contains data from 12 hospitals that have costs per patient records based on activities and clinical records. Adverse events were identified through the Patient Safety Indicators (validated in the Spanish Health System) created by the Agency for Healthcare Research and Quality together with indicators of the EuroDRG European project. RESULTS: This study included 245,320 episodes with a total cost of 1,308,791,871€. Approximately 17,000 patients (6.8%) experienced an adverse event, representing 16.2% of the total cost. Adverse events, adjusted by diagnosis-related groups, added a mean incremental cost of between €5,260 and €11,905. Six of the 10 adverse events with the highest incremental cost were related to surgical interventions. The total incremental cost of adverse events was € 88,268,906, amounting to an additional 6.7% of total health expenditure. CONCLUSIONS: Assessment of the impact of adverse events revealed that these episodes represent significant costs that could be reduced by improving the quality and safety of the Spanish Health System.
Authors: Juan Enrique Martínez de la Plata; José Antonio Morales-Molina; Maria Ángeles Castro Vida; Juan José Pérez Lázaro; Pedro Acosta Robles Journal: Eur J Hosp Pharm Date: 2017-09-27
Authors: Marta Riu; Pietro Chiarello; Roser Terradas; Maria Sala; Enric Garcia-Alzorriz; Xavier Castells; Santiago Grau; Francesc Cots Journal: PLoS One Date: 2016-04-07 Impact factor: 3.240
Authors: Marta Riu; Pietro Chiarello; Roser Terradas; Maria Sala; Enric Garcia-Alzorriz; Xavier Castells; Santiago Grau; Francesc Cots Journal: Medicine (Baltimore) Date: 2017-04 Impact factor: 1.889
Authors: Antonio Martínez-Sabater; Carlos Saus-Ortega; Mónica Masiá-Navalon; Elena Chover-Sierra; María Luisa Ballestar-Tarín Journal: Nurs Rep Date: 2022-02-14
Authors: Priscila Giraldo; Luke Sato; Jose M Martínez-Sánchez; Mercè Comas; Kathy Dwyer; Maria Sala; Xavier Castells Journal: BMJ Open Date: 2016-08-30 Impact factor: 2.692